Drug Profile

PP 1131

Alternative Names: P. aeruginosa phages cocktail - PHAXIAM Therapeutics; PHAGOBURN Pseudomonas phage therapy - PHAXIAM Therapeutics; PP-1131

Latest Information Update: 28 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pherecydes Pharma
Developer PHAXIAM Therapeutics
Class Pseudomonas phages
Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
05 Mar 2021 Discontinued - Phase-I/II for Burn infections in France, Belgium (Topical) (Pherecydes Pharma pipeline, March 2021)
16 Feb 2021 Pherecydes Pharma has patent protection for anti-Pseudomonas aeruginosa and anti-E. Coli phages in the US

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com